Association between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study

Medicine (United States)

Volumn 95, Issue 15, 2016, Pages

  Peng, Yen Chun ^a,b   Lin, Cheng Li ^c,d   Yeh, Hong Zen ^a,b   Chang, Chi Sen ^a   Wu, Yu Lin ^b   Kao, Chia Hung ^e,f  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c China Medical University Hospital   (China)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; TAIWAN; CASE CONTROL STUDY; DISEASE COURSE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROPENSITY SCORE; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPENSITY SCORE; PROTON PUMP INHIBITORS; RENAL REPLACEMENT THERAPY; RISK FACTORS; TAIWAN;

EID: 84964650319     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003363     Document Type: Article

References (27)

1. Vela MF. Medical treatments of GERD: the old and new. Gastroenterol Clin North Am. 2014;43:121-133.
2. Fortinsky KJ, Bardou M, Barkun AN. Role of medical therapy for nonvariceal upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am. 2015;25:463-478.
3. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl 2):S27-32.
4. Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2010;24:193-201.
5. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3:E166-E171.
6. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6:461-470.
7. Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545-553.
8. Geevasinga N, Coleman PL, Webster AC, et al. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4:597-604.
9. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11:381-385.
10. Ray S, Delaney M, Muller AF. Proton pump inhibitors and acute interstitial nephritis. BMJ (Clinical research ed). 2010;341:.
11. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150.
12. Cekin AH, Boyacioglu S, Gursoy M, et al. Gastroesophageal reflux disease in chronic renal failure patients with upper GI symptoms: multivariate analysis of pathogenetic factors. Am J Gastroenterol. 2002;97:1352-1356.
13. Fallone CA, Mayrand S. Gastroesophageal reflux and hyperacidity in chronic renal failure. Perit Dial Int. 2001;21(Suppl 3):S295-S299.
14. Kawaguchi Y, Mine T, Kawana I, et al. Gastroesophageal reflux disease in chronic renal failure patients: evaluation by endoscopic examination. Tokai J Exp Clin Med. 2009;34:80-83.
15. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68:65-72.
16. Database NHIR. Taiwan, http://nhird.nhri.org.tw/en/Background.html 2015.
17. Peng YC, Lin CL, Hsu WY, et al. Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study. Br J Clin Pharmacol. 2015;80:755-761.
18. Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73:1774-1780.
19. WHO International Working Group for Drug Statistics Methodology, W.C.C.f.D.S.M., WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, Introduction to Drug Utilization Research. 2003, Geneva, Switzerland: World Health Organization.
20. WHO Collaborating Center for Drugs Statistics Methodology:ATC/DDD Index, http://www.whocc.no/atc-ddd-index/?code=A10BH. 2015.
21. Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am J Med. 1992;93:472-473.
22. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-1127.
23. Bell J, Blacker N, LeBlanc V, et al. Prescribing for older people with chronic renal impairment. Aust Fam Physician. 2013;42:24-28.
24. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Neph. 2006;2:80-91.
25. Martin KJ, Gonzalez EA, Slatopolsky E. Clinical consequences and management of hypomagnesemia. J Am Soc Nephrol. 2009;20:2291-2295.
26. Cunningham J, Rodŕiguez M, Messa P. Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. Clin Kidney J. 2012;5(Suppl 1):i39-i51.
27. Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175:1527-1529.